Barney Tate, Thyagarajan Anita, Sahu Ravi P
Boonshoft School of Medicine, Dayton, OH 45435, USA.
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Dayton, OH 45435, USA.
Med Sci (Basel). 2025 Aug 19;13(3):143. doi: 10.3390/medsci13030143.
Combining immune checkpoint inhibitors (ICIs) and anti-angiogenic pharmacologic agents is an encouraging therapeutic approach in the treatment of non-small cell lung cancer (NSCLC). Currently, the only FDA-approved therapy combining an immune checkpoint inhibitor and a vascular endothelial growth factor (VEGF) inhibitor is atezolizumab, bevacizumab, and chemotherapy in first-line metastatic NSCLC patients. However, the combination of nivolumab, a programmed death-1 (PD-1) inhibitor, and bevacizumab has also shown encouraging results in patients with NSCLC with minimal adverse effects, respectively. This communication aims to highlight the efficacy of nivolumab and bevacizumab in NSCLC patients without sensitizing mutations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS proto-oncogene 1 (ROS1). In addition, the combination of nivolumab/atezolizumab and bevacizumab with other therapeutic agents is also discussed. We also underscore the adverse effects and limitations of such combinations in NSCLC patients. Future studies should focus on large-scale trials and biomarker identification to establish the benefits of these combination therapies in NSCLC patients.
将免疫检查点抑制剂（ICI）与抗血管生成药物联合使用，是治疗非小细胞肺癌（NSCLC）的一种令人鼓舞的治疗方法。目前，美国食品药品监督管理局（FDA）唯一批准的将免疫检查点抑制剂与血管内皮生长因子（VEGF）抑制剂联合使用的疗法，是用于一线转移性NSCLC患者的阿替利珠单抗、贝伐单抗和化疗。然而，程序性死亡-1（PD-1）抑制剂纳武单抗与贝伐单抗的联合使用，在NSCLC患者中也显示出了令人鼓舞的效果，且不良反应最小。本通讯旨在强调纳武单抗和贝伐单抗在无表皮生长因子受体（EGFR）、间变性淋巴瘤激酶（ALK）或ROS原癌基因1（ROS1）敏感突变的NSCLC患者中的疗效。此外，还讨论了纳武单抗/阿替利珠单抗与贝伐单抗与其他治疗药物的联合使用。我们还强调了此类联合治疗在NSCLC患者中的不良反应和局限性。未来的研究应侧重于大规模试验和生物标志物识别，以确定这些联合疗法对NSCLC患者的益处。
